Hundreds attend ‘Walk MS: Longmeadow' to raise funds and awareness
LONGMEADOW, Mass. (WWLP) – Community members rallied together to raise funds and awareness for Multiple Sclerosis.
Nearly 400 people showed that people living with Multiple Sclerosis (MS) are not alone. The National Multiple Sclerosis Society's 'Walk MS: Longmeadow' raises awareness and funds to find a cure for the disease.
Fight at Amherst Regional Middle School prompts shelter-in-place, ongoing investigation
About one million people live with MS in the United States. It's unpredictable, and often disabling, but there are resources through the National MS Society, like Walk MS, that help people affected live their best lives. One walker shared why she chose to participate.
'I'm walking because I was recently diagnosed with MS, and I figured this would be a great way to feel supported by the community,' said Degenais Romero of Holyoke.
Romero's relatives also weighed in on their impact.
'It means a lot because it shows how you're supportive, and how everyone's come together,' said Fabian Morales of West Springfield. 'It's a community thing.'
Another attendee was diagnosed nearly 12 years ago, and she said having her village by her side makes all the difference.
'It's a daily fight, and I'm just so happy and blessed to have everybody during this journey,' said Marlaina Ray of Wilbraham.
Organizers said they expect walkers to raise nearly $70,000 for the National MS Society throughout Saturday's event. They were seen waving paddles showing their connection to the disease, whether they're living with MS or supporting a loved one.
Sidewalks were full of orange, the color for MS Awareness, with each step towards the finish line and one step closer to finding a cure.
WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 hours ago
- CBS News
Man biking to all 92 Dunkin' locations in Boston to raise money for multiple sclerosis research
Man riding bike to all the Dunkin' locations in Boston to raise money for multiple sclerosis Man riding bike to all the Dunkin' locations in Boston to raise money for multiple sclerosis Man riding bike to all the Dunkin' locations in Boston to raise money for multiple sclerosis A Cambridge man spent National Donut Day biking to every Dunkin' in Boston to raise money for multiple sclerosis research. Adam Bigelow planned to eat one Munchkin at all of the 92 Dunkin' locations. He decided to do this ride to honor his girlfriend, who was diagnosed with MS last summer. He has raised more than $5,000 for a charity bike ride to the tip of Cape Cod with the Multiple Sclerosis Society later this month. "I thought it would be really fun and very Boston to go to every single Dunkin' and raise awareness about why I'm doing this," Bigelow told WBZ-TV. He began his journey at 4:30 a.m. Friday in East Boston and planned to end it in Allston-Brighton. "Outpouring of support" "All the Dunkin employees have been holding these signs and cheering me on; that outpouring of support really keeps me going. It's been a ton of fun so far," Bigelow said. "It's so cool to see that everybody has been banding together behind me to help make this happen." The company heard about his story and gave Bigelow more than 200 gift cards to give out along the way. He said the company also gave him special swag to hand out to some people who donate to his fundraising page. "It's so great that our location is part of Adam's journey," said Dunkin' store manager Richter Racine. "It makes me and her [his girlfriend] feel very supported in all this, especially the messages from other people who have had challenges with this disease, who have been reaching out. That's really special and makes me feel like, you know, it's such a great cause," Bigelow said. Follow the bike ride on National Donut Day You can track Bigelow's route on his Instagram page and possibly snag a gift card from him alongside a free donut with any drink purchase at Dunkin' for National Donut Day.
Medscape
5 hours ago
- Medscape
Experimental MS Drug Nearly Eliminates Disease Activity
PHOENIX — Frexalimab, a second-generation anti-CD40 ligand monoclonal antibody provides extended tight control of multiple sclerosis (MS) whether measured by relapse or brain imaging at 2-year follow-up, results of an open-label extension (OLE) of a phase 2 trial showed. 'At week 96, there was almost complete suppression of new gadolinium-enhancing lesions with very similar pattern seen with new or enhancing T2 lesions,' said study investigator Stephen Krieger, MD, professor of neurology, Icahn School of Medicine at Mount Sinai, New York City. Two phase 3 international studies with this drug are already enrolling. 'Part of the interest in frexalimab and anti-CD40 therapies is the idea that one can modulate both B- and T-cell activity without cell depletion,' explained Krieger, who presented the long-term open-label data on May 29 at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting. Near Complete Disease Suppression The latest data suggest frexalimab is fulfilling its promise. Over follow-up to date, there has been nearly complete suppression of gadolinium-enhancing (Gd+) lesions on MRI among those taking the dose now being tested in the phase 3 trials. At 2 years, with an annualized relapse rate of 0.08%, 92% of patients were relapse-free. The randomized portion of this phase 2 trial attracted attention when it was published a year ago in The New England Journal of Medicine , but the 2-year results showed that the efficacy and safety observed at 12 weeks persist. In the controlled trial, 129 patients with relapsing MS were randomized to 300-mg, 400-mg, 600-mg, or 1200-mg frexalimab or matching placebos. Suppression of Gd+ lesions was the primary endpoint. At 12 weeks, the adjusted mean of new Gd+ lesions was 1.4 in the combined placebo groups but 0.3 in the 300-mg frexalimab group and 0.2 in the 1200-mg group. Of those who participated in the randomized portion of the phase 2 trial, 97% continued into the long-term OLE. The OLE consisted of two arms: 1200-mg frexalimab administered intravenously every 4 weeks or 300-mg frexalimab administered subcutaneously every 2 weeks. At the end of 2 years, when 82% of those enrolled in the OLE were still on medication, the adjusted mean for new T1-weighted Gd+ lesions ranged from 0.1 to 0.3 across study arms whether on continuous frexalimab or switched from placebo to frexalimab. For those who were initiated on the 1200-mg dose in the controlled portion of the trial and remained on this dose for the OLE, the mean was 0.1. For the secondary endpoint of new or enlarging T2 lesions, the suppression at 2 years was almost the same. Again, the adjusted mean for new lesions across all arms ranged from 0.1 to 0.3. For those receiving the 1200-mg dose, the mean was 0.2. Mean T2 lesion volume increased in the placebo arm but not in the treatment arms during the randomized phase. After entering the OLE, T2 lesion volume fell in placebo patients now on active therapy. In the 1200-mg arm, the fall in lesion volume during the randomized phase continued into the first 24 weeks of the OLE. After 24 weeks, the lesion volume remained suppressed with no return toward baseline. Those initiated on placebo never caught up after switching to frexalimab. Relapse Rare — 2% at 96 Weeks On the 1200-mg dose of frexalimab, only 8% had any relapse recorded over the extended follow-up. In half, there was a single relapse. Only 2% had three or more relapses. While the Expanded Disability Status Scale score declined slightly among placebo patients once started on active therapy, there was no change from baseline through 96 weeks in patients started on any active therapy. As postulated by earlier preclinical and clinical studies, frexalimab had no effect on lymphocyte counts over time. Over the 96-week follow-up, levels of immunoglobulins remained unchanged, according to Krieger who showed graphs with straight lines for these values over the course of the OLE. Due to the potential of suppressing activation of both T and B cells over time, anti-CD40 therapies have long been considered a promising mechanism for control of MS. However, clinical development of first-generation drugs was abandoned because of an association with thromboembolism. 'Frexalimab has been engineered to avoid these events through a change in the Fc receptors with reduces downstream inflammatory events,' said Krieger. The long-term data support this premise. Over 2 years, there was one pulmonary embolism, but this exception was observed in a patient with a viral illness and a genetic predisposition for an inflammatory response, according to Krieger. When surveying other adverse events, 'nothing jumps out' in the OLE relative to the randomized phase. One potential exception is a rise in liver function tests observed in two (4%) patients on the 1200-mg dose. Only one of these patients discontinued therapy, and the levels returned to normal over time in both. The effects of the anti-CD40 mechanism on both the adaptive and innate immune systems suggest frexalimab might offer efficacy for both progressive and relapsing MS. In the ongoing phase 3 program, one of the trials (FREXALT) is enrolling patients with relapsing MS. The other (FREVIVA) is enrolling patients with progressive disease. Fulfilling its Promise Commenting on the results, Amit Bar-Or, MD, Chief of the Multiple Sclerosis Division, the Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, described frexalimab as 'a very interesting drug.' He agreed that the CD40 ligand is a promising target in MS but cautioned that these phase 2 data cannot answer the most interesting questions. This includes the more robust evidence of safety and efficacy from phase 3 trials, but it remains unclear whether the benefits extend beyond controlling relapsing disease. 'I think there is particular interest in whether it will also show extended benefit in progressive MS, and this will be a major focus of interest from the next set of studies,' Bar-Or said.
Yahoo
5 hours ago
- Yahoo
Demyelinating Diseases Therapeutics Market to Reach USD 45 Billion by 2034, Growing at 6.3% CAGR
Demyelinating Diseases Therapeutics Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- The global market for demyelinating diseases therapeutics is witnessing notable growth and transformation, fueled by the increasing prevalence of neurological disorders and the introduction of innovative treatment solutions. Valued at approximately USD 25 billion in 2024, the market is projected to reach an estimated USD 45 billion by 2034, progressing at a steady Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period from 2025 to 2034. Download PDF Brochure: A major contributor to this expansion is the rising incidence of multiple sclerosis (MS), along with other related disorders such as neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and chronic inflammatory demyelinating polyneuropathy (CIDP). The market is undergoing significant advancements through personalized medicine, biologics, and digital health integrations, shaping the way therapies are developed and delivered. Market Segmentation: A Detailed Breakdown The demyelinating diseases therapeutics market is categorized across several parameters including product type, therapeutic application, disease type, route of administration, distribution channels, therapeutic class, and patient demographics. Among product types, monoclonal antibodies, corticosteroids, and immunomodulators dominate due to their high efficacy and role in managing autoimmune responses central to these diseases. Multiple Sclerosis (MS) remains the largest disease segment due to its global prevalence, impacting nearly 2.8 million individuals worldwide. This segment benefits from a strong drug pipeline and sustained investment in research and development. In contrast, diseases like NMO and CIDP, though less prevalent, are becoming more prominent due to improved diagnostic capabilities and novel drug approvals. When it comes to therapeutic applications, Disease-Modifying Therapies (DMTs) are pivotal. These therapies reduce relapse rates and slow disease progression, particularly in MS, capturing the lion's share of the market. Symptomatic treatments, though secondary in market size, are essential for improving patients' quality of life and remain indispensable in overall disease management strategies. Route of Administration and Distribution Channels The preferred routes of administration in this market include injectable, oral, and infusion-based methods. Injectables lead due to their rapid efficacy and widespread use in administering monoclonal antibodies. However, oral therapies are quickly gaining popularity for their convenience and higher patient adherence, which could shift the administration landscape in coming years. From a distribution perspective, hospital pharmacies remain the dominant channel, especially for therapies requiring medical supervision or administration. Meanwhile, online pharmacies are emerging as strong contenders due to their convenience and role in chronic disease management. This growth is driven by increased internet penetration, telehealth services, and changing consumer behavior. Therapeutic Class and Demographic Insights In terms of therapeutic classification, biologics are leading the charge. These include monoclonal antibodies and recombinant proteins that target specific immune pathways. Biologics offer superior efficacy and fewer side effects, making them the preferred option in many treatment regimens. However, small molecules continue to hold value due to their affordability, oral availability, and ease of production, especially in cost-sensitive markets. Demographically, adult patients comprise the majority due to the typical onset age of MS and related disorders. However, pediatric treatments are on the rise as early diagnosis improves. The geriatric population is another growing segment, supported by the aging global population and increasing incidence of neurological conditions in older adults. These patients often require specialized care due to comorbidities and age-related drug interactions. Browse full Report - Market SegmentationType of Demyelinating Disease - Multiple Sclerosis (MS) - Neuromyelitis Optica (NMO) - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Acute Disseminated Encephalomyelitis (ADEM) Therapeutic Application - Disease-Modifying Therapies (DMTs) - Symptomatic Treatments - Corticosteroids - Monoclonal Antibodies - Other Immunotherapies & Supportive Care Route of Administration - Oral - Injectable (Subcutaneous, Intravenous) - Infusion Distribution Channel - Hospital Pharmacy - Retail Pharmacy - Online Pharmacy Therapeutic Class - Biologics - Small Molecules - Non-Biologics Patient Demographics - Adults - Pediatric - Geriatric Regional Insights and Global Landscape North America currently commands the largest market share, accounting for around 45% of global revenue in 2024. This dominance is underpinned by advanced healthcare systems, widespread access to therapies, and high levels of R&D investment. The U.S., in particular, plays a significant role with supportive regulatory policies and well-established pharmaceutical players. Europe follows closely, contributing approximately 30% to the market. Growth in this region is propelled by increasing awareness, government-supported healthcare systems, and a favorable environment for clinical research. Countries like Germany, France, and the UK are key hubs for drug development and patient care. The Asia-Pacific region is the fastest-growing market with a projected CAGR of 8% through 2034. Factors such as economic development, expanding healthcare infrastructure, and rising disease prevalence contribute to this rapid growth. Nations like China, India, and Japan are investing heavily in healthcare, which supports both access and innovation in therapeutic offerings. Latin America and the Middle East & Africa are also emerging as regions with untapped market potential. While they currently hold smaller shares, their projected CAGRs of 7% and 6% respectively reflect strong future growth, particularly in urban centers with improving access to care. Key Market Drivers The momentum in this market is largely attributed to scientific and technological advancements, including the development of next-generation therapies like monoclonal antibodies and targeted biologics. The rise of personalized medicine, where treatments are tailored based on patient-specific genetic and biomarker profiles, is reshaping therapeutic strategies. Regulatory developments are also influential. Accelerated approval pathways, especially for orphan and breakthrough therapies, have reduced time-to-market for promising treatments. In tandem, increased global healthcare spending, particularly in neurological and autoimmune sectors, is bolstering the adoption of advanced therapies. Challenges and Restraints Despite promising growth, the market faces a number of hurdles. One major challenge is the high cost of therapies, especially biologics, which limits access for patients in low- and middle-income regions. Prolonged regulatory approval timelines and complex compliance requirements can also delay product launches and increase costs for manufacturers. Supply chain disruptions, particularly in biopharmaceutical manufacturing, further complicate delivery and availability. The sector is also vulnerable to clinical trial failures, which can derail product pipelines and investor confidence. Additionally, generic and biosimilar competition can undercut revenues once patents expire, necessitating continuous innovation. Buy Now : Opportunities and Emerging Trends The market is rich with opportunities for expansion and innovation. Digital health technologies, such as telemedicine platforms and remote monitoring tools, are increasingly integrated into care pathways, enhancing both outcomes and convenience. These technologies also support real-time data collection and predictive analytics, aiding personalized care. Additionally, emerging markets offer considerable potential for growth. As awareness rises and infrastructure improves, pharmaceutical companies are investing in these regions to tap into large, underserved patient populations. The trend toward strategic partnerships, mergers, and acquisitions is another significant development. Collaborations between pharmaceutical firms and tech companies, particularly in AI-driven drug discovery and patient management, are redefining the way therapies are developed and delivered. Key Competitors Biogen Inc. Novartis International AG Roche Holding AG Sanofi S.A. Celgene Corporation (a Bristol-Myers Squibb Company) Merck KGaA Teva Pharmaceutical Industries Ltd. Genzyme Corporation (a Sanofi Company) EMD Serono, Inc. AbbVie Inc. GSK (GlaxoSmithKline) Vertex Pharmaceuticals Incorporated Pfizer Inc. Janssen Pharmaceuticals (a Johnson & Johnson Company) Horizon Therapeutics plc Recent Strategic Developments Company Name: Biogen Inc. Month & Year: August 2023 Type of Development: Product Launch Detailed Analysis: Biogen launched its latest multiple sclerosis (MS) therapy, an oral medication named Alectinib, in August 2023. This drug represents a significant advancement in the treatment landscape for MS, targeting a previously underserved patient demographic. The launch is crucial as the MS market increasingly shifts toward oral therapies that offer improved safety and convenience over traditional injections. Biogen's investment in clinical studies demonstrates their commitment to addressing unmet clinical needs. The release not only strengthens Biogen's portfolio but also rekindles competitive dynamics in the MS therapeutics market. Other companies may need to accelerate their research and focus on innovative delivery mechanisms to retain market share, indicating a potential uptick in R&D spending across the industry. Company Name: Novartis International AG Month & Year: July 2023 Type of Development: Regulatory Approval Detailed Analysis: In July 2023, Novartis received expedited approval from the FDA for its drug ofatumumab aimed at treating neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, debilitating condition, and this regulatory advancement opens new pathways for patients who have historically faced limited treatment options. This approval underlines a broader trend in the industry towards personalized medicine and targeted therapies. The positive regulatory news also strengthens Novartis's position in the demyelinating diseases market, compelling competitors to prioritize novel therapeutic approaches. As regulatory environments evolve, this approval may set a precedent that encourages pharmaceutical companies to innovate and invest heavily in rare disease therapies. Company Name: AbbVie Inc. Month & Year: September 2023 Type of Development: Merger Detailed Analysis: AbbVie entered a strategic merger with a biotech firm specializing in CNS (central nervous system) diseases in September 2023. This merger is pivotal not only for AbbVie's growth but also signifies a consolidation trend within the CNS therapeutics sector. By integrating innovative technologies and pipeline assets, AbbVie aims to bolster its competitive edge significantly in the demyelinating diseases market. This merger highlights the increasing interconnectedness of the pharmaceutical ecosystem, pivoting around collaboration to enhance therapeutic effectiveness and patient outcomes. Industry observers anticipate that this will prompt increased mergers and acquisitions in the sector as firms seek similar synergies to expedite drug development processes. Company Name: Sanofi S.A. Month & Year: October 2023 Type of Development: Product Launch Detailed Analysis: Sanofi unveiled a new monoclonal antibody therapy for treating relapsing forms of MS in October 2023, expanding its treatment arsenal significantly in this field. The introduction of this therapy reflects a commitment to advancing treatment modalities through innovative science. Furthermore, the development showcases a broader industry trend toward biologics and targeted therapies for demyelinating diseases. Market responses indicate that healthcare professionals and payers are eager for alternatives that provide safety and efficacy. This influx of new treatment options may fuel competitive pressure on existing therapies, leading to potential price adjustments and altering market dynamics. Company Name: Teva Pharmaceutical Industries Ltd. Month & Year: November 2023 Type of Development: Partnership Detailed Analysis: Teva announced a strategic partnership with a technology firm to collaborate on AI-driven approaches to MS treatment and patient management in November 2023. This partnership underscores a growing trend of incorporating technology into healthcare to enhance drug discovery and patient outcomes. By utilizing AI, Teva aims to streamline clinical research and tailor therapies to individual patient needs, thereby enhancing therapeutic efficacy. The collaboration could reshape how the pharmaceutical industry conducts research and develops therapies for demyelinating diseases, prompting competitors to explore similar integrations of advanced technologies, ultimately driving innovation in the market. This report is also available in the following languages : Japanese (脱髄疾患治療薬市場), Korean (탈수초성 질환 치료제 시장), Chinese (脱髓鞘疾病治疗市场), French (Marché des thérapies contre les maladies démyélinisantes), German (Markt für Therapeutika gegen demyelinisierende Erkrankungen), and Italian (Mercato terapeutico delle malattie demielinizzanti), etc. Request Sample Pages: More Research Finding – Human Granulocytic Ehrlichiosis Drug Market The market for drugs targeting Human Granulocytic Ehrlichiosis (HGE) is valued at approximately $320 million. Given the rising incidence of tick-borne diseases and increased awareness among healthcare professionals, the market is projected to grow significantly, reaching an estimated value of $580 million by 2034. This indicates a compound annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Lymphopenia Therapeutics Market The global lymphopenia therapeutics market is valued at approximately $3.2 billion, driven by increasing awareness of immune disorders and advancements in biologics and immunotherapies. The market is projected to grow significantly, reaching an estimated $6.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period of 2025 to 2034. Cytochrome C Antibody Market The global Cytochrome C Antibody market is valued at approximately $210 million in 2024, driven by increasing research activities in cell apoptosis and related diseases. The market is projected to reach around $350 million by 2034, reflecting a robust growth trajectory fueled by advancements in biotechnology and rising prevalence of cancer and neurodegenerative disorders. AMPK Antibody Market The AMPK antibody market is valued at approximately $1.2 billion, fueled by the growing demand for research products in metabolic diseases and cancer therapy. The market is projected to reach about $2.5 billion by 2034, reflecting accelerating advancements in biotechnology and personalized medicine. Threonine Protein Kinase Chk1 Antibody Insights 2024 The market for Threonine Protein Kinase Chk1 Antibodies is poised for significant growth, with a projected market value of approximately $250 million by 2024. Over the forecast period from 2025 to 2034, the market is expected to expand, reaching an estimated value of $500 million. This growth represents a compound annual growth rate (CAGR) of around 8.5%. TrkC Antibody Market The TrkC antibody market was valued at approximately $1.5 billion in 2024, driven by increasing research funding and rising demand for targeted cancer therapies. This niche market is expected to reach around $3.2 billion by 2034, reflecting a robust growth trajectory. The projected Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 8.2%. Androgen Antibody Market The androgen antibody market is poised for significant growth, with an estimated market value of approximately $1.2 billion in 2024. Projections indicate that this market could expand to around $2.8 billion by 2034, reflecting increasing demand for advanced diagnostic and therapeutic options in conditions related to androgen imbalance. This growth represents a Compound Annual Growth Rate (CAGR) of about 9.0% during the forecast period from 2025 to 2034. Herpesvirus Entry Mediator HVEM Protein Market The global market for the Herpesvirus Entry Mediator (HVEM) protein is valued at approximately $150 million, primarily driven by its applications in immunotherapy and viral research. The market is poised for significant growth, with a projected value of $300 million by 2034, representing a robust Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period from 2025 to 2034. Histone Deacetylase 1 HDAC1 Antibody Market The market for Histone Deacetylase 1 (HDAC1) antibodies is poised for significant growth, valued at approximately $250 million in 2024. This sector is expected to reach an estimated $750 million by 2034, driven by the rising prevalence of cancer and neurodegenerative diseases, which HDAC1 inhibitors target. The compound annual growth rate (CAGR) is projected at approximately 12% during the forecast period from 2025 to 2034. Prostaglandin-endoperoxide Synthase 2 COX-2 Antibody Market The global market for Prostaglandin-endoperoxide Synthase 2 (COX-2) antibodies is valued at approximately $1.6 billion in 2024, with a projected market value of around $3.2 billion by 2034. This growth corresponds to a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. Fecal Incontinence Therapeutics Market The fecal incontinence therapeutics market is poised for significant growth, valued at approximately $1.2 billion in 2024. By 2034, this market is projected to reach around $3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period of 2025–2034. POEMS Syndrome Treatment Market The global market for POEMS Syndrome diagnostic and therapeutic solutions is valued at approximately $700 million. The market is poised for significant growth, with projections estimating a market value of around $1.3 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.5% during the forecast period from 2025 to 2034. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market The Non-Alcoholic Steatohepatitis (NASH) therapeutics and diagnostics market was valued at approximately $4.2 billion in 2024 and is projected to reach $12 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of around 12% during the forecast period of 2025-2034. mRNA Vaccine and Therapeutics Raw Material Market The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034. Gene Editing Kit Market The gene editing kit market is projected to reach a value of approximately $5.4 billion in 2024, driven by advancements in CRISPR technology and increased applications in synthetic biology and personalized medicine. The market is expected to grow significantly, with a forecasted value of $13.2 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period from 2025 to 2034. Nanoparticles Market The global nanoparticles market is projected to reach a value of approximately $60 billion in 2024, driven by advancements in nanotechnology across various sectors, including healthcare, electronics, and energy. The market is expected to grow significantly, achieving a projected value of $120 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Bispecific T Cell Engager Therapeutics Future Trends The bispecific T cell engager (BiTE) therapeutics market is valued at approximately $7.5 billion, driven by rising incidences of hematologic malignancies and solid tumors. The market is projected to grow significantly, with an estimated value of around $20 billion by 2034. This represents a compound annual growth rate (CAGR) of about 12.3% over the forecast period from 2025 to 2034. Molecular Cancer Therapeutics Market The global molecular cancer therapeutics market is projected to reach approximately $120 billion in 2024, driven by advancements in personalized medicine and an increasing number of targeted therapies. The market is expected to grow at a robust CAGR of 8.5% from 2025 to 2034, indicating a significant demand for innovative treatments that address specific genetic and molecular profiles of tumors. Single-Cell Dispenser Market The global single-cell dispenser market is valued at approximately $580 million in 2024 and is projected to reach around $1.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
